AMRX FY 2024 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

FY 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$2.8B+16.7% YoY

Gross Profit

$1.0B36.5% margin

Operating Income

$249M8.9% margin

Net Income

-$117M-4.2% margin

EPS (Diluted)

$-0.38

Cash Flow

Operating Cash Flow

$295M

Free Cash Flow

$220M

Stock-Based Comp.

$28M

Balance Sheet

Total Assets

$3.5B

Total Liabilities

$3.5B

Stockholders' Equity

-$109M

Cash & Equivalents

$111M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.8B	$2.4B	+16.7%
Gross Profit	$1.0B	$864M	+18.1%
Operating Income	$249M	$204M	+22.0%
Net Income	-$117M	-$84M	-39.2%